Pfizer is to research nanomedicines for several diseases in a partnership with Bind Therapeutics that could be $210m per product developed.
The deal focuses on Bind’s targeted therapeutics called Accurins, which the company says can outperform conventional drugs by selectively seeking out diseased tissues and cells.
This means there is a higher drug concentration at the necessary site of action, meaning a more effective and safe medicine.
No specific therapy areas were mention by the company, although Bind has said Accurins have the potential to improve patient outcomes in oncology, inflammatory diseases and cardiovascular disorders.
Under the terms of the agreement, both companies will work on preclinical research, while Pfizer will then have the exclusive option to pursue development and commercialisation of selected Accurins.
In return, Bind could receive upfront and development milestone payments totalling $50m and regulatory and sales milestone payments of about $160m for each Accurin commercialised. There will also be tiered royalties on potential future sales.
This is the second major deal Bind has made with a large pharma company this year following a $226m+ deal with Amgen in January.
As noted in the PMLiVE article, Future imperfect: How breakthrough technology can support healthcare, nanotechnology is predicted to have a large impact on healthcare in the coming years, with nanomaterials already being used in the production processes of other industries.
This includes products such as plasma screens, car paints and batteries for mobile phones.
“This is our second collaboration focused on developing novel Accurins based on Bind’s platform for targeted and programmable therapeutics and further validates the importance of targeted nanomedicines as a strategic technology for the pharmaceutical industry,” said Scott Minick, president and CEO of Bind.